BREAKING: Futures Await Nvidia Earnings Eli Lilly (ELI) partner and cancer treatment developer Rigel Pharmaceuticals (RIGL) is nearing a buy point of a cup base. The drug stock got a boost after Rigel reported strong third-quarter earnings and raised its sales guidance in early November. The IBD 50 Growth Stocks To Watch has outperformed 94% of stocks that Investor's Business Daily tracks with its 152%… Related news Rigel Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating IBD Videos Ge ...

©2025 Investor's Business Daily, LLC. All Rights Reserved. *Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. Information in Investor's Business Daily is for informational and educational purposes only and s ...